Document is current
Any future updates will be listed below
-
Authors
Schwarz, Franziska Maria https://orcid.org/0009-0001-9741-5784
Klotz, Daniel Martin
Yang, Ruming https://orcid.org/0000-0003-3593-3735
Brux, Melanie
Buchholz, Frank https://orcid.org/0000-0002-4577-3344
Harb, Hani
Link, Theresa
Wimberger, Pauline
Theis, Mirko
Kuhlmann, Jan Dominik https://orcid.org/0000-0003-3820-3017
- License Information
-
More Information
Article History
Received: 30 August 2024
Revised: 6 January 2025
Accepted: 29 January 2025
First Online: 6 February 2025
Competing interests
: FMS: no conflict of interest. DMK: no conflict of interest. MB: no conflict of interest. RY: no conflict of interest. FB: no conflict of interest. HH: no conflict of interest. TL: Scientific talks: MSD, Pfizer, Novartis, Teva, Tesaro, Roche, Amgen, Clovis, Lilly, GSK, Gilead; Travel/Kongress-Support: Pharma mar, Roche, Pfizer, MSD, Celgene, Clovis, Daiichi Sankyo; Consulting or Advisory Role: Amgen, Roche, Tesaro, MSD, Pfizer, Lilly, Myriad, Esai, GSK, Gilead, Daiichi Sankyo. PW: Honoraria: AstraZeneca, MSD Oncology, Eisai, Novartis/ Pfizer, Roche Pharma AG, Amgen, Pfizer; Consulting or Advisory Role: Amgen, Astra Zeneca, MSD Oncology, Novartis, Roche Pharma AG, Tesaro, PharmaMar; Travel, Accommodations, Expenses: RochePharma AG. MT: no conflict of interest. JDK: no conflict of interest.
